[ad_1]
US FDA Approves Emergency Use of ‘Regeneron’, Administered by Trump
Reporter Kim Kyung-hee [email protected]
Check-in: 2020-11-22 18:21:11Review: 2020-11-22 18:22:19Published: 2020-11-22 18:25:01 (p. 12)
Regeneron, a biotech company approved for emergency use by the United States Food and Drug Administration (FDA), shows a production facility in New York for the treatment of COVID-19 antibodies. On the 21st (local time), the FDA approved the emergency use of Regeneron’s ‘REGN-COV2’ antibody treatment. The drug was used in the treatment of Corona 19 by US President Donald Trump and received public attention. AP Yonhap News Yonhap News
The COVID-19 antibody treatment from US biotech company Regeneron has been approved for emergency use by the US Food and Drug Administration (FDA).
According to US media such as Bloomberg News and the Wall Street Journal (WSJ) on the 21st (local time), the FDA is a Regeneron antibody treatment for the treatment of COVID-19 patients (including high-risk patients over 65 years) with mild or moderate symptoms older than 12 years. Approved emergency use of ‘REGN-COV2’.
Drug approval for patients 12 years and older
“Continue evaluation of safety and efficacy”
12 million people infected with corona are confused
Recommendation to refrain from traveling on Thanksgiving
According to the FDA, in clinical trials in patients infected with COVID-19, high-risk patients who received this drug decreased the rate of hospitalization or went to the emergency room for symptoms of COVID-19 within 28 days of the baseline compared to control group receiving placebo (placebo). . The FDA said the safety and efficacy of this therapy in the treatment of COVID-19 will continue to be evaluated.
‘REGN-COV2’ is a treatment that combines two monoclonal (monoclonal) antibodies, and it is a drug that was used as a treatment analyzing and evaluating antibodies in the blood of Corona 19 cured patients to select only antibodies that can neutralize the virus. It is developed using an isolated monoclonal antibody to bind only to a virus-specific antigen.
The drug was especially used in the treatment of Corona 19 by President Donald Trump of the United States and received public attention. Trump said he was taking this drug at the time and “immediately got better. I felt amazing, ”he praised.
As a terminated monoclonal antibody treatment, it is the second to be approved by the FDA, following the monoclonal antibody treatment ‘LY-CoV555’ being developed by Eli Lilly, a US pharmaceutical company.
However, as Eli Lilly and Regeneron recently suspended clinical trials in critically ill patients with corona19, doubts about the effectiveness and safety of treatments have increased worldwide. WP reported that, like Eli Lilly’s antibody treatment, Regeneron’s antibody treatment could be in short supply as it is time-consuming to manufacture.
Meanwhile, the reproliferation tax is accelerating, with cumulative corona19 infection in the United States topping 12 million on the 21st. Johns Hopkins University in the US counted the cumulative number of confirmed corona19 cases in the US. On this day at 1,219,960. The number of people infected with Corona 19 in the United States represents 20.8% of cumulative infections (57,898,000 people) worldwide. In the United States, Corona 19 is expanding fiercely after the fall of October. Hospitalized patients due to Corona 19 are also writing new records every day. According to the Corona 19 monitoring project, 82,178 people were hospitalized on the 20th.
Among these, health experts warn that Thanksgiving (26), the largest holiday in the United States, could be a risk factor for accelerating the spread of Corona 19. The Centers for Disease Control and Prevention Department of Diseases (CDC) advised against traveling to visit family and friends, but experts are still concerned that many will find family and friends.
The National Automobile Association said it expects the number of commuters to decline by at least 10% on Thanksgiving this year compared to the same time last year, but the number of commuters is still expected to hit 50. millions. In addition, the American media reported that Chicago’s O’Hare International Airport, which is called the hub of air travel, is already busy with Thanksgiving travelers.
Reporter Kim Kyung-hee [email protected] Some news from Yonhap
